Resources from the same session
LBA49 - Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study
Presenter: Edward Garon
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1192MO - Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study
Presenter: Natasha B. Leighl
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1193MO - Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2
Presenter: Catherine A. Shu
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA50 - A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naïve patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22
Presenter: Anne-Marie Dingemans
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA51 - EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
Presenter: Miranda Gogishvili
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1194MO - Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results
Presenter: Luis Paz-Ares
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Discussion LBA49, 1192MO and 1193MO
Presenter: Sai-Hong Ou
Session: Mini oral session - NSCLC, metastatic
Resources:
Slides
Webcast